The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
A newly published cache of CRLs includes six novel oncology drugs.
Autogene cevumeran goes on hold in adjuvant bladder cancer.
The deal for ISB 2001 is worth $700m up front.
Multispecifics newly into the clinic include Car-Ts from Essen and Unicar.
ESO-T01 delivers its first four multiple myeloma case reports.
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
